Therapeutic efficacy using the small molecule inhibitor of β-Catenin Responsive Transcription-3 (iCRT3) that disrupts β-catenin and TCF4 interaction has also been observed in prostate cancer [55,235,236]. The gene discussed is TCF4; the disease is prostate carcinoma.